港股异动 | 佳兆业健康(00876)逆市涨超40% 公司拟收购青海制药控股权拿下稀缺麻精牌照

智通财经网03-23

智通财经APP获悉，佳兆业健康(00876)逆市涨超40%，截至发稿，涨30%，报0.117港元，成交额496.96万港元。消息面上，佳兆业健康近日发布公告，宣布以总价2160.37万元收购青海制药控股权，预计5月下旬完成全部交割。本次交易意味着集团正式切入准入门槛极高的麻醉及精神类药品制造领域，产业链布局进一步延伸，将成为推动公司估值体系重塑的重要变量。公开资料显示，青海制药作为国家指定的麻精...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2621175723?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20260323/20260323101803_45229.png?x-oss-process=image/format,jpg/quality,q_60","is_english":false,"pubTime":"2026-03-23 10:17","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2621175723","market":"fut","top_or_hot":-1,"title":"港股异动 | 佳兆业健康(00876)逆市涨超40% 公司拟收购青海制药控股权 拿下稀缺麻精牌照","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，佳兆业健康(00876)逆市涨超40%，截至发稿，涨30%，报0.117港元，成交额496.96万港元。消息面上，佳兆业健康近日发布公告，宣布以总价2160.37万元收购青海制药控股权，预计5月下旬完成全部交割。本次交易意味着集团正式切入准入门槛极高的麻醉及精神类药品制造领域，产业链布局进一步延伸，将成为推动公司估值体系重塑的重要变量。公开资料显示，青海制药作为国家指定的麻精...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1417183.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 佳兆业健康(00876)逆市涨超40% 公司拟收购青海制药控股权 拿下稀缺麻精牌照</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 佳兆业健康(00876)逆市涨超40% 公司拟收购青海制药控股权 拿下稀缺麻精牌照\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-23 10:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1417183.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，佳兆业健康(00876)逆市涨超40%，截至发稿，涨30%，报0.117港元，成交额496.96万港元。消息面上，佳兆业健康近日发布公告，宣布以总价2160.37万元收购青海制药控股权，预计5月下旬完成全部交割。本次交易意味着集团正式切入准入门槛极高的麻醉及精神类药品制造领域，产业链布局进一步延伸，将成为推动公司估值体系重塑的重要变量。公开资料显示，青海制药作为国家指定的麻精...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1417183.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1417183.html","article_id":"2621175723","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20260323/20260323101803_45229.png?x-oss-process=image/format,jpg/quality,q_60"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621175723","pubTimestamp":1774232232,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"佳兆业健康(00876)逆市涨超40%，截至发稿，涨30%，报0.117港元，成交额496.96万港元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","BK1191":"制药","BK4585":"ETF&股票定投概念","BK1222":"医疗保健用品","01477":"欧康维视生物-B","BK1574":"生物医药B类股","VXUS":"国际股票ETF-Vanguard","00876":"佳兆业健康"},"translate_title":"Changes in Hong Kong stocks | Kaisa Health (00876) rose by more than 40% against the market. The company plans to acquire a controlling stake in Qinghai Pharmaceutical to obtain a scarce hemp essence license","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00876":1.5,"01477":1.5,"VXUS":1.5},"content_text":"智通财经APP获悉，佳兆业健康(00876)逆市涨超40%，截至发稿，涨30%，报0.117港元，成交额496.96万港元。消息面上，佳兆业健康近日发布公告，宣布以总价2160.37万元收购青海制药控股权，预计5月下旬完成全部交割。本次交易意味着集团正式切入准入门槛极高的麻醉及精神类药品制造领域，产业链布局进一步延伸，将成为推动公司估值体系重塑的重要变量。公开资料显示，青海制药作为国家指定的麻精药品生产基地，拥有国内领先的麻醉药品及一类精神药品品种体系，牌照极为稀缺、准入门槛极高。公司产品覆盖原料药、麻精制剂和化学制剂三大板块，现有124款产品、156种规格，其中21款为独家品种，广泛应用于住院手术镇痛、重症急救等核心临床场景。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621175723","isCrawlerRequest":true}

港股异动 | 佳兆业健康(00876)逆市涨超40% 公司拟收购青海制药控股权 拿下稀缺麻精牌照

精彩评论

港股异动 | 佳兆业健康(00876)逆市涨超40% 公司拟收购青海制药控股权拿下稀缺麻精牌照